AMRX Stock — Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (AMRX)

Updated October 16, 2026.

AMRX is a Stock. Total return is 667.2% over the past 17.8 years, 476.2 points behind SPY at 1143.4%.

Amneal Pharmaceuticals is a global biopharmaceutical company that develops, manufactures, and distributes generic drugs, injectable medications, biosimilars, and specialty branded pharmaceuticals through three segments: Affordable Medicines (offering various dosage forms and delivery systems), Specialty (focusing on central nervous system and endocrine disorders, including Parkinson's disease treatments), and AvKARE (serving government agencies and institutional customers). The company does not currently have an established distribution schedule to shareholders. Amneal appeals to equity investors seeking exposure to the pharmaceutical and generic drug manufacturing sector.

AMRX performance versus SPY

Price and return data through 2026-10-16.

Total return is 667.2% over the past 17.8 years, 476.2 points behind SPY at 1143.4%. Over the past year its total return — price change plus distributions reinvested — is 94.3%. Its deepest 1-year drawdown was 22.3%.

AMRX key facts

Asset type

Stock

Asset class

Equity

Inception date

01/14/2009

Distribution frequency

None

Last close

$19.18 (as of 2026-10-16)

Market cap

$6,680,317,798

Average volume

2286719.0

Beta

1.218

Payout ratio

0.0%

P/E ratio

39.14

Forward P/E

6.2972

EPS

$0.49

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AMRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 22.3%.

Who may consider AMRX — and who may not

It is a weaker fit for investors who need monthly cash flow (AMRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on AMRX

• All tickers starting with A

Tagged: Healthcare, Pharmaceutical.

Frequently asked questions